Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Cluster-tic syndrome as the initial manifestation of multiple sclerosis.
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Puma, but not noxa is essential for oligodendroglial cell death.
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.
Receptos, Inc. - Current Report: United States Securities and Exchange Commission Form 8-K
Considering the influence of stimulation parameters on the effect of conventional and high-definition transcranial direct current stimulation.
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1.
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis.
European Congress of Immunology 2012
Risk factors for rare diseases can be risky to define: PML and natalizumab.
Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases.
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
The delta-subunit of the epithelial sodium channel (ENaC) enhances channel activity and alters proteolytic ENaC activation.
Clinical profile of malay children with optic neuritis.
Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
Early relapses, onset of progression, and late outcome in multiple sclerosis.
Embryonic stem cell lines derived from human blastocysts.
Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.
Guillain-Barré syndrome: clinical profile and management.
Physiopathological Roles of p2x Receptors in the Central Nervous System.
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
Regional Susceptibility to TNF-α Induction of Murine Brain Inflammation via Classical IKK/NF-κB Signalling.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Pages
« first
‹ previous
…
131
132
133
134
135
136
137
138
139
…
next ›
last »